Breaking News

UPM, Amerigen Enter Long-Term Mfg. Pact

April 3, 2014

Will supply two ANDA products under a 10-year commercial agreement

UPM, a division of Gregory Pharmaceutical Holdings, Inc., has entered an agreement with Amerigen Pharmaceuticals, Inc. to manufacture two ANDA products for a 10- year commercial supply term. Also, UPM may potentially develop and supply several additional ANDA products for Amerigen under the agreement.
Back in July 2013, UPM acquired Pfizer’s 475,000 sq.-ft. manufacturing facility in Bristol, TN, which is where all of these products will eventually be made.
Dr. John M. Gregory, chairman and chief executive officer of Gregory Pharmaceutical Holdings, Inc., said, "UPM has been working with Amerigen for the past three years. We have a strong working relationship with their company and are impressed with their technical team and their business development approach. We believe this agreement cements our partnership with Amerigen. Also, it is another example of UPM's transition from a company that formerly focused on only early stage development, but now, provides a full range of solid dose commercial services for our clients."
Jonathan Embleton, chief business officer of Amerigen, said, "Amerigen looks forward to a long relationship with UPM.  We are excited about our upcoming product portfolio and the role UPM will play in providing products to market."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus